Chris Dinsmore, Ph.D. joined Kronos Bio in 2020 and served as Chief Scientific Officer until February 2024. Chris has more than 25 years of experience in biomedical R&D. Prior to joining Kronos Bio, Chris was an Entrepreneur-in-Residence at Third Rock Ventures where he focused on discovering and launching new innovative therapeutic companies. Previously, he was Vice President and Head of Chemistry at FORMA Therapeutics, responsible for the advancement of a pipeline of transformative medicines and applying an array of discovery chemistry platforms and approaches to target classes in epigenetics and protein homeostasis. Earlier, Chris was at Merck Research Laboratories for 19 years where he held various positions in medicinal chemistry. His project experiences in discovery and development have been in therapeutic categories that include cancer, hematology, sickle cell disease, asthma, and rheumatoid arthritis, leading to the advancement of numerous development compounds into clinical trials. Chris also serves as a member of the WARF Therapeutics Advisory Board, helping to move therapeutic innovations forward in drug discovery and development. After graduating from Bowdoin College with a bachelor’s degree in chemistry and art, he earned his Ph.D. in synthetic organic chemistry from the University of Minnesota in Minneapolis, and then carried out postdoctoral research in chemical synthesis at Harvard University.